US › Healthcare

Werewolf Therapeutics Inc (HOWL)

US · Healthcare · Biotechnology

$0.41+12.79%
Last close · 2026-08-04

Latest quarter · ended 2026-06-30

Revenue
$21.0M
Net profit
$3.7M
Profit YoY
+120.4%
EPS
$0.08
EPS estimate
$-0.28
Net margin
17.5%

EPS came in at 0.08 against a street estimate of -0.28 — a beat of 128.6%.

Key statistics

Market cap
$17.2M
Forward P/E
0.0
P/B
1.05
Book value
$0.25
EPS (TTM)
$-0.73
52-week high
$2.38
52-week low
$0.27
50-day MA
$0.39
200-day MA
$0.74
Beta
0.30

Analyst view

Analysts rate Werewolf Therapeutics Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $7.00.

Shareholding

Insiders
1.40%
Institutions
26.70%

Largest institutional holders

FundStake
RA Capital Management, LLC13.75%
Vanguard Capital Management, LLC2.51%
MPM Oncology Impact Management LP2.49%
Lynx1 Capital Management, LP1.35%
Sphera Funds Management Ltd.1.29%
DC Funds, LP1.21%
Squadron Capital Management LLC1.16%
Renaissance Technologies Corp1.06%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Werewolf Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.